Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1995-06-01
1998-06-30
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
4241751, 4241941, 42419611, 4242041, A61K 39385, A61K 3912
Patent
active
057730032
ABSTRACT:
Hapten-carrier conjugates capable of eliciting anti hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Anti-hapten antibodies elicited compete with free hapten upon subsequent challenge of a vaccinated individual. Methods of preparing the conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
REFERENCES:
patent: 4045420 (1977-08-01), Soffer et al.
patent: 4197237 (1980-04-01), Leute et al.
patent: 4235864 (1980-11-01), Kaul et al.
patent: 4375414 (1983-03-01), Strahilevitz
patent: 4376825 (1983-03-01), Rubenstein et al.
patent: 4620977 (1986-11-01), Strahilevitz
patent: 4666837 (1987-05-01), Harford
patent: 4791067 (1988-12-01), Sheiman
patent: 4813924 (1989-03-01), Strahilevitz
patent: 4834973 (1989-05-01), Strahilevitz
patent: 5019384 (1991-05-01), Gefter
patent: 5037645 (1991-08-01), Strahilevitz
patent: 5256409 (1993-10-01), Blincko
patent: 5268276 (1993-12-01), Holmgren
patent: 5283066 (1994-02-01), Liu et al.
Curreru, R. et al., (1993) Society for Neuroscience 754.4 (Abstract).
Ambre, et al., "A Kinetic Model of Benzoylechonine Disposition after Cocaine Administration in Humans", Journal of Analytical Toxicology, vol. 15, 1991, 17-20.
Berkower, "Synthetic T Cell Epitope Peptides Used for Desensitization: Theoretical and Clinical Considerations", Paul-Ehrlich-Institut, Sep. 7-10, 1993.
Bonese, "Changes in heroin self-administration by a rhesus monkey after morphine immunization", Nature, vol. 252, Dec. 1974.
Gallacher, "A potential vaccine for cocaine abuse prophylaxis?", Immunopharm., vol. 27. 1994, 79-81.
Holmgren, et al., "Strategies for the Induction of Immune Responses at Mucosal Surfaces . . . ", Am. J. Trop. Med. Hyg., 1994, pp. 42-54.
Inaba, "Cocaine: Pharmacokinetics and biotransformation in man", SFBS Symposium on Frontiers in Cocaine Research, Quebec, Canada, Jun. 15, 1988, pp. 1154-1157.
Jatlow, "Cocaine: Analysis, Pharmacokinetics, and Metabolic Disposition", The Yale Journal of Biology and Medicine, vol. 61, 1988, pp. 105-113.
Jindal, et al., "Mass Spectrometric Studies of Cocaine Disposition in Animals . . . ", Journal of Pharmaceutical Sciences, vol. 78, No. 12, 1989, pp. 1009-1014.
Kantak, et al., "Acute and multiple injection effects of magnesium on responding maintained by Cocaine, . . . ", Pharm. Biochem. and Behavior, vol. 41, 1992, pp. 415-423.
Manganaro, et al., "Oral Immunization: Turning Fantasy into Reality", Int. Arch. Immunol., vol. 103, 1994, pp. 223-233.
Stok, et al., "Conversion of orally induced supression of the mucosal immune response to ovalbumin into stimulation by conjugating . . . ", Vaccine, vol. 12, 1994, No. 6, pp. 521-526.
Slos, et al., "Recombinant cholera toxin B subunit in Escherichia coli: high-level secretion, purification and characterization", Protein Expression and Purification, vol. 5, 1994, pp. 518-526.
Witkin, "Pharmacotherapy of Cocaine Abuse: Preclinical Development", Neurosci. and Biobehav. Reviews, vol. 18, No. 1, 1994, pp. 121-142.
Jones-Witters and Witters, Drugs and Society--A Biological Perspective, Wadsworth Health Sciences Division, 1983, Wadsworth, Inc., Belmont, California 94002, pp. 142-147.
Wu, et al., "Compression of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen . . . ", Vaccine, 1994, vol. 12, No. 3, pp. 215-222.
Kovalev et al. (1979) Khim. Farm. (USSR) pp. 615-618 with translation.
Chuong et al. (1977) Annales Pharmaceutiques Francaises 35:257-264 (Translation).
Harless et al. Abstract: Active Immunization Prevents Analgesic and Reinforcing Effects of Cocaine, Twenty-Fourth Annual Western Psychology Conference, Apr. 1995.
Wainer et al. (1972) Science 176:1143-1145.
Wainer et al. (1972) Science 178:647-648.
Spector et al. (1970) Science 168:1347-1348.
Wainer et al. (1973) The Journal of Immunology 110:667-673.
Van Vunakis et al. (1972) The Journal of Pharmacology and Experimental Therapeutics 180:514-521.
Spector (1971) The Journal of Pharmacology and Experimental Therapeutics 178:253-258.
Castro et al. (1980) Eur. J. Biochem 104:331-340.
Castro et al. (1975) Biochemical and Biophysical Research Communications 67:583-589.
Matsushita et al. (1974) Biochemical and Biophysical Research Communications 57:1006-1010.
Castro et al. (1985) Biochemical Archives 1:173-183.
Castro et al. (1986) Research Communications in Chemical Pathology and Pharmacology 51:393-404.
Decato et al. (1977) Journal of Immunological Methods 18:201-213.
Killian et al. (1978) Pharmacology Biochemistry & Behavior 9:347-352.
Berkowitz (1972) Science 178:1290-1292.
Berkowitz et al. (1975) Life Sciences 15:1017-1028.
Zimmermann et al. (1976) Proc. West. Pharmacol. Soc. 19:260-265.
Spector et al. (1973) Pharmacological Reviews 25:281-291.
Spector (1976) Biochemical Pharmacology 25:2427-2428.
Lomax et al. (1973) Proc. West. Pharmacol. Soc. 16:252-256.
Wainer et al. (1973) Nature 241:537-538.
Miller et al. (1974) Proc. West. Pharmacol. Soc. 17:69-72.
Herndon (1975) Life Sciences 17:151-158.
Schmidt et al. (1971) The Journal of Clinical Investigation 50:866-871.
Colburn (1980) Drug Method Rev. 11:223-262.
Pentel et al. (1991) Drug Meth. & Disp. 19:24-28.
Kovalev et al. (1980) Khim. Pharm. pp. 200-204.
Exley Mark Adrian
Fox Barbara Saxton
Gefter Malcolm L.
Greenstein Julia Lea
Powers Stephen P.
Achutamurthy Ponnathapura
ImmuLogic, Inc.
LandOfFree
Hapten-carrier conjugates for use in drug-abuse therapy and meth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hapten-carrier conjugates for use in drug-abuse therapy and meth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hapten-carrier conjugates for use in drug-abuse therapy and meth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1856203